CRISPR Gene Editing Newsletter
Issue #55September 21, 20267 studies

Base editing fixed a motor neuron disease gene in mice — and in lab-grown human nerve tissue

Gene editing had a big week — and not just in the usual places.

From spider mites to human embryos to brain organoids, the tools are getting sharper, the targets are getting stranger, and the limits are getting harder to ignore.

🧠 Base Editing Rescues a Motor Neuron Disease — in Mice and Human Organoids

  • Researchers targeted a single mutation (P285L in the TFG gene) that causes a rare inherited motor neuron disease sharing features with ALS. They screened base editors in patient-derived stem cells, picked the best one, and delivered it via a virus injected near the spinal cord in mice.
  • The result: treated mice lived longer, kept more motor neurons, and lost less axon tissue in their ventral nerve roots. In lab-grown human neuromuscular organoids, the same editor reduced toxic protein clumping and cut neuronal death.
  • The approach simultaneously addresses the gain-of-function toxicity and the loss-of-function deficit from the same mutation — a dual problem that has made inherited motor neuron diseases hard to treat with a single strategy.

Why it matters: This is proof-of-concept that base editing — which rewrites a single DNA letter without cutting the double helix — can work in a living nervous system and in human tissue models for a disease with no good treatment options.

🔗 Molecular therapy. Advances Journal Article 🗓️ Sep 15

Key Findings

⚗️ Base Editing in Human Embryos: Cleaner, But Not Clean Enough

  • Scientists delivered a base editor as a protein at fertilization, achieving edits at every copy of the PCSK9 gene with no insertions or deletions detected — and embryos developed normally to the blastocyst stage.
  • The catch: delivering the editor as mRNA caused frequent embryo arrest from guide-independent DNA damage, and bystander edits at unintended sites were mosaic (inconsistent across cells). The authors conclude current tools preclude clinical use in reproduction.
💡 Efficient base editing in human embryos is possible — but mosaicism and off-targets remain disqualifying.
🔗 Nature Journal Article 🗓️ Sep 15

💪 A Base Editor for Duchenne Muscular Dystrophy Hearts

  • Using a split dual-virus system, researchers delivered a base editor targeting splice sites in the dystrophin gene in human heart cells derived from DMD patient stem cells. Even modest editing levels in 3D engineered heart patches trended toward reducing arrhythmic activity — moving the electrical behavior closer to a milder disease form.
  • The approach aims to skip a broken exon rather than replace the whole gene, a more deliverable strategy given the dystrophin gene's enormous size.
💡 Even partial base editing may soften DMD's cardiac phenotype in lab heart tissue.
Top 20% journal 🔗 Human gene therapy Journal Article 🗓️ Sep 16

🦠 A 3.5-Hour CRISPR Test That IDs 15 Mycobacterium Species at Once

  • A new diagnostic platform called CANDI compartmentalizes CRISPR reactions into color-coded nanodroplets, enabling a 16-target panel that distinguishes 15 clinically relevant mycobacterial species in a single run — including species that cause infections now surpassing tuberculosis in some regions.
  • Tested on 230 clinical respiratory samples, it hit 97.1% sensitivity and 99.7% specificity against standard culture-based identification, with results in under 3.5 hours versus days for culture.
💡 Multiplexed CRISPR diagnostics can match culture-level mycobacterial ID in hours, not days.
🥇 Top 1% journal 🔗 Science translational medicine Journal Article 🗓️ Sep 16

🔬 Long Reads Catch Mosaic CRISPR Edits That Short Reads Miss

  • Mosaicism — where different cells in the same organism carry different edits — is a known side effect of CRISPR, but low-frequency structural variants are easy to miss with standard sequencing. A new long-read approach provides deep, single-molecule resolution of editing outcomes at target sites.
  • The method is designed to give a more complete and unbiased picture of what actually happened after an edit, including rare large deletions that could matter for safety assessments.
💡 Standard sequencing likely undercounts structural variants after CRISPR editing.
🥇 Top 1% journal 🔗 Genome medicine Journal Article 🗓️ Sep 18

🧫 A Probiotic Yeast Engineered to Break Down Lactose

  • Using CRISPR-Cas9, researchers integrated a lactose-digesting enzyme gene from a fungus into three spots in the genome of Saccharomyces boulardii — a clinically used probiotic yeast. The triple-integration strain showed an 11.76-fold increase in enzyme activity over single-integration strains and could grow on cheese whey as a food-grade substrate without losing its characteristic stress tolerance.
  • The work establishes a validated toolkit for engineering this probiotic chassis for therapeutic protein delivery.
💡 Triple-site gene integration gives a probiotic yeast nearly 12-fold more lactose-busting enzyme output.
🎖️ Top 10% journal 🔗 Microbiological research Journal Article 🗓️ Sep 18

🩸 Alternative Cas Proteins Outperform the Standard in Sickle Cell Editing

  • When researchers compared three CRISPR proteins head-to-head in stem cells from sickle cell disease patients, SaCas9 beat the standard SpCas9 at correcting the sickle mutation and at hitting a key fetal hemoglobin switch. AsCas12a led on a different target and produced the highest fetal hemoglobin levels — the therapeutic goal.
  • Both alternatives also showed fewer off-target edits than SpCas9, suggesting a better safety profile for clinical use.
💡 For sickle cell editing, the standard CRISPR protein may not be the best tool for every target.
🔗 Cell biomaterials Journal Article 🗓️ Sep 16

Implications

Base editing is moving fast — from mouse spinal cords to human organoids to embryos — but this week's human embryo data underscores a recurring tension: efficiency and safety don't always travel together. The field still lacks a clear threshold for how much mosaicism or off-target editing is acceptable before any of these tools enter a clinical setting.

Studies in this issue

Primary sources used for this newsletter.

  1. Base editing may improve inherited nerve cell disease in mice and lab-grown patient cells
    main storyMolecular therapy. Advances2026-09-15PMID 42740795
  2. Using CRISPR-Cas9 to increase enzyme production in Saccharomyces boulardii
    key findingMicrobiological research2026-09-18PMID 42759161
  3. Highly efficient gene editing of PCSK9 with normal development in human embryos
    key findingNature2026-09-15PMID 42742174
  4. A fast CRISPR nanodroplet test for directly identifying mycobacteria species in clinical samples
    key findingScience translational medicine2026-09-16PMID 42748215
  5. Precise analysis of CRISPR-Cas9 gene editing results and mixed cell changes using highly accurate long DNA reads
    key findingGenome medicine2026-09-18PMID 42754893
  6. Creating a Gene Editor Delivered by Virus to Treat Duchenne Muscular Dystrophy
    key findingHuman gene therapy2026-09-16PMID 42745513
  7. Highly Efficient and Precise Gene Editing in Blood Stem and Progenitor Cells Using SaCas9 and AsCas12a Ultra
    key findingCell biomaterials2026-09-16PMID 42746631

Continue reading

All CRISPR Gene Editing issues